Last reviewed · How we verify
Bentracimab (PB2452) Infusion
Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects.
Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects. Used for Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures.
At a glance
| Generic name | Bentracimab (PB2452) Infusion |
|---|---|
| Sponsor | SFJ Pharmaceuticals, Inc. |
| Drug class | Heparin reversal agent; monoclonal antibody |
| Target | Unfractionated heparin (UFH) |
| Modality | Small molecule |
| Therapeutic area | Hematology; Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Bentracimab is a selective heparin-binding monoclonal antibody designed to rapidly neutralize unfractionated heparin in patients who require urgent reversal of anticoagulation. It binds directly to UFH molecules, preventing their interaction with antithrombin and restoring normal coagulation. This mechanism allows for rapid hemostasis in bleeding emergencies or before urgent procedures in heparinized patients.
Approved indications
- Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures
Common side effects
- Thrombotic events
- Infusion reactions
- Hypersensitivity reactions
Key clinical trials
- Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure (PHASE3)
- Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old (PHASE2)
- Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bentracimab (PB2452) Infusion CI brief — competitive landscape report
- Bentracimab (PB2452) Infusion updates RSS · CI watch RSS
- SFJ Pharmaceuticals, Inc. portfolio CI